Neurogenetic Testing Market Report 2026

The neurogenetic testing market size has grown rapidly in recent years. It will grow from $0.7 billion in 2025 to $0.79 billion in 2026 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to early adoption of pcr-based genetic testing, rising prevalence of inherited neurological disorders, increased use of microarray platforms, development of early diagnostic techniques, initial integration of genetic screening into clinical workflows.

The neurogenetic testing market size is expected to see rapid growth in the next few years. It will grow to $1.24 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to growing demand for next-generation sequencing, increasing expansion of clinical exome sequencing, rising investment in genetic research, development of advanced molecular diagnostic tools, growing adoption of personalized neurological treatment approaches. Major trends in the forecast period include rising adoption of whole-exome sequencing technologies, increasing use of pcr-based neurological genetic tests, growing implementation of microarray analysis, expansion of testing for rare neurological genetic disorders, growing demand for early diagnosis and predictive testing.

The rising prevalence of neurological disorders is expected to drive the growth of the neurogenetic testing market. Neurological disorders encompass conditions that affect the nervous system, including the brain, spinal cord, and nerves. Their prevalence is influenced by factors such as genetic predisposition, infections, trauma, toxins, autoimmune responses, and degeneration. Neurogenetic testing plays a critical role in improving the diagnosis, treatment, and management of these disorders by providing personalized insights into genetic risk factors, guiding treatment strategies, and enabling individuals and families to make informed healthcare decisions, thereby enhancing patient care and outcomes. For example, in October 2023, the World Federation of Neurology, a UK-based charity, reported that neurological disorders are now the second-leading cause of death and the primary cause of disability worldwide, affecting over 40 percent of the global population in 2023, with the number of individuals living with brain diseases expected to nearly double by 2050. As a result, the increasing prevalence of neurological disorders is expected to fuel demand for neurogenetic testing.

The rising prevalence of cancer is also expected to propel the growth of the neurogenetic testing market. Cancer is characterized by the uncontrolled division of abnormal cells that destroy healthy tissue. Factors driving the increase in cancer cases include obesity, inherited genetic abnormalities, and infections such as hepatitis B and C, Epstein-Barr virus (EBV), and human papillomavirus (HPV). Neurogenetic testing is vital in cancer management, helping identify high-risk patients, guiding personalized treatment decisions, evaluating prognoses, and providing care tailored to each patient’s genetic profile and family history. For instance, in January 2024, data from the American Cancer Society, a US-based non-profit organization, projected 2,001,140 new cancer cases and 611,720 cancer deaths in the United States in 2024, compared with 1,958,310 cases and 609,820 deaths in 2023. Therefore, the growing incidence of cancer is contributing to the expansion of the neurogenetic testing market.

Companies in the neurogenetic testing market are focusing on developing innovative products, such as whole-genome sequencing, to improve the accuracy and comprehensiveness of genetic analysis, enabling more personalized testing for neurological disorders. Whole-genome sequencing (WGS) is a method that determines the complete DNA sequence of an individual’s genome, providing a comprehensive view of genetic information. For example, in March 2024, Nucleus Genomics, a US-based genetic analysis company, launched a DNA analysis platform that empowers individuals to understand their genetic predispositions and make informed health decisions. With advanced technology and expert genetic counseling services, Nucleus Genomics is poised to transform genetic testing, making whole-genome sequencing more accessible and revolutionizing personalized genomic medicine.

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children’s, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services.

North America was the largest region in the neurogenetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neurogenetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the neurogenetic testing market by increasing the cost of imported sequencing equipment, diagnostic reagents, and molecular analysis instruments essential for genetic testing workflows. These rising costs particularly affect hospitals, specialty clinics, and diagnostic laboratories in regions dependent on imported testing technologies such as Europe and Asia-Pacific. Segments involving whole-exome sequencing, microarray kits, and PCR testing face supply chain delays and higher operational expenses. However, tariffs are also encouraging domestic biotechnology manufacturing, strengthening regional production capabilities, and supporting innovation in cost-effective genetic testing solutions.

The neurogenetic testing market research report is one of a series of new reports that provides neurogenetic testing market statistics, including neurogenetic testing industry global market size, regional shares, competitors with a neurogenetic testing market share, detailed neurogenetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the neurogenetic testing industry. This neurogenetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neurogenetic testing is a form of genetic testing that aims to identify genetic variations linked to neurological disorders or conditions affecting the nervous system. It is employed for diagnosing, predicting, and managing neurological conditions, as well as supporting research and the development of personalized treatment strategies in neurology and genetics.

The key types of neurogenetic testing include microarray analysis, whole-exome sequencing (WES), multiplex ligation-dependent probe amplification (MLPA), polymerase chain reaction (PCR) tests, and other methods. Microarray analysis is a technique used to examine the expression levels of thousands of genes simultaneously in neurogenetic testing. These tests are applied to a range of conditions, including rare genetic disorders, cancer, cystic fibrosis, sickle cell anemia, Duchenne muscular dystrophy, thalassemia, Huntington’s disease, Fragile X syndrome, and other diseases. The tests are utilized by various end-users, such as hospitals, specialty clinics, research institutes, and diagnostic laboratories.

The neurogenetic testing market includes revenues earned by entities by providing services such as diagnostic testing, predictive testing, carrier screening, and prenatal testing and related products such as genetic testing kits, DNA sequencing platforms, and bioinformatics software. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.